Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies
暂无分享,去创建一个
Jintanat Ananworanich | Nelson Michael | Jerome H. Kim | J. Ananworanich | N. Michael | S. DaFonseca | M. Ramgopal | R. Fromentin | N. Chomont | Nicolas Chomont | E. Merlini | Sandrina DaFonseca | Claire Vandergeeten | Rémi Fromentin | Moti Ramgopal | Amanda McNulty | Esther Merlini | Mariam B. Lawani | Wendy Bakeman | C. Vandergeeten | Amanda Mcnulty | Wendy Bakeman | M. Lawani
[1] R. Siliciano,et al. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient , 2013, PLoS pathogens.
[2] R. Siliciano,et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.
[3] Y. Pommier,et al. Azido-Containing Diketo Acid Derivatives Inhibit Human Immunodeficiency Virus Type 1 Integrase In Vivo and Influence the Frequency of Deletions at Two-Long-Terminal-Repeat-Circle Junctions , 2004, Journal of Virology.
[4] R. Siliciano,et al. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. , 2005, Methods in molecular biology.
[5] Geneviève Boucher,et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.
[6] C. Rouzioux,et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir , 2010, Journal of medical virology.
[7] H. Fleury,et al. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA , 2000, AIDS.
[8] J. Farrar,et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. , 2011, AIDS.
[9] C. Rouzioux,et al. The measurement of HIV-1 viral load in resource-limited settings: how and where? , 2007, Clinical laboratory.
[10] Namshin Kim,et al. Human Immunodeficiency Virus Integration Efficiency and Site Selection in Quiescent CD4+ T Cells , 2009, Journal of Virology.
[11] B. Levine,et al. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. , 2008, Virology.
[12] C. Rouzioux,et al. LTR Real-Time PCR for HIV-1 DNA Quantitation in Blood Cells for Early Diagnosis in Infants Born to Seropositive Mothers Treated in HAART Area ( ANRS CO 01 ) , 2008 .
[13] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[14] V. Natarajan,et al. Impact of the DNA extraction method on 2-LTR DNA circle recovery from HIV-1 infected cells. , 2013, Journal of virological methods.
[15] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[16] Sarah B. Laskey,et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.
[17] A. Fauci,et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. , 1989, Journal of immunology.
[18] D. Cooper,et al. HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy , 2014, Journal of Virology.
[19] U. O’Doherty,et al. Quantitation of integrated proviral DNA in viral reservoirs , 2013, Current opinion in HIV and AIDS.
[20] Rebecca Hoh,et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. , 2013, The Journal of infectious diseases.
[21] Sarah Palmer,et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.
[22] F. Buonaguro,et al. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.
[23] S. Lewin,et al. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? , 2011, AIDS.
[24] P. Sonigo,et al. Evidence for Gene Expression by Unintegrated Human Immunodeficiency Virus Type 1 DNA Species , 2004, Journal of Virology.
[25] Mario Roederer,et al. T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.
[26] A. Bhandoola,et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. , 2011, Virology.
[27] John L. Sullivan,et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.
[28] F. Bushman. Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker. , 2003, AIDS.
[29] J. Mellors,et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.
[30] C. B. Hare,et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.
[31] P. Massip,et al. Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART , 2005, AIDS.
[32] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[33] M. Lederman,et al. Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.
[34] Avettand‐Fènoël Véronique,et al. LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) , 2009 .
[35] R. Siliciano,et al. Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.
[36] R. Siliciano,et al. Experimental approaches to the study of HIV-1 latency , 2007, Nature Reviews Microbiology.
[37] D. Nickle,et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.
[38] T. Calvez,et al. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection , 2003, AIDS.
[39] P. Sonigo,et al. Analysis of Early Human Immunodeficiency Virus Type 1 DNA Synthesis by Use of a New Sensitive Assay for Quantifying Integrated Provirus , 2003, Journal of Virology.
[40] J. Mills,et al. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes , 1996, Journal of virology.
[41] R. Paredes,et al. Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART , 2011, PLoS pathogens.
[42] S. Lewin,et al. Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. , 2010, The Journal of infectious diseases.
[43] L. Montaner,et al. Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials , 2012, AIDS.
[44] T. Perneger,et al. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions , 2004, AIDS.
[45] Alan S Perelson,et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.
[46] M. Lederman,et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. , 2013, Blood.
[47] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[48] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.